Reductions in asthma exacerbations and improvements in lung function vs placebo 1,2
The VOYAGE study was a randomised, double-blind, placebo-controlled phase 3 study designed to demonstrate the efficacy and safety of DUPIXENT over a period of up to 52 weeks in children 6–11 years of age with uncontrolled moderate-to-severe* asthma1
Efficacy with DUPIXENT + standard of care (SOC) compared to placebo1
-
DUPIXENT significantly reduced asthma exacerbations vs placebo4
Significant exacerbation reduction through week 52 (VOYAGE primary endpoint)
77.1% (182/236) of children treated with DUPIXENT had no severe exacerbations over 52 weeks vs 59.6% (68/114) in the placebo group1DUPIXENT significantly reduced asthma exacerbations vs placebo4
Significant exacerbation reduction through week 52 (VOYAGE primary endpoint)
77.1% (182/236) of children treated with DUPIXENT had no severe exacerbations over 52 weeks vs 59.6% (68/114) in the placebo group1 -
DUPIXENT demonstrated improvements to lung function measured by change in FEV11,2
Rapid and sustained improvement in lung function over 52-week period (VOYAGE secondary endpoint)
Key secondary endpoint in VOYAGE measuring lung function was change from baseline in percent predicted pre-BD FEV1 at Week 12DUPIXENT demonstrated improvements to lung function measured by change in FEV11,2
Rapid and sustained improvement in lung function over 52-week period (VOYAGE secondary endpoint)
Key secondary endpoint in VOYAGE measuring lung function was change from baseline in percent predicted pre-BD FEV1 at Week 12
DUPIXENT PRE FILLED -SYRINGE
Adult and adolescent trial design
Learn more about how the clinical trials have been designed.
Asthma control and QoL
Learn more about how DUPIXENT can help improve asthma control in adults and adolescents with severe asthma.
- Bacharier LB, et al. 2021 N Engl J Med;385(24):2230-2240. doi:10.1056/ NEJMoa2106567
- Data on file, Sanofi US. LIBERTY ASTHMA VOYAGE. CSR. 2020.
- Juniper EF, et al. Eur Respir J 2010;36(6):1410-1416. doi:10.1183/09031936.00117509.
- Poachanukoon O, et al. Pediatr Allergy Immunol 2006;17(3):207-212. doi:10.1111/j.1399-3038.2005.00349.
**Some patients in this study classed as having severe asthma no longer fall into this category, owing to changes in the definition of high-dose ICS.
†The responder rate was defined as an improvement in score of 0.5 or more.
References
MAT-XU-2204214 (v1.0) | Date of preparation: May 2023
